The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Massimo AndreoniMatteo BassettiSalvatore CorraoFrancesco Giuseppe De RosaVincenzo EspositoMarco FalconePaolo Antonio GrossiFederico PeaNicola PetrosilloCarlo TasciniMario VendittiPierluigi VialePublished in: Expert review of anti-infective therapy (2021)
The board identifies some specific subgroups of patients with ABSSSIs who could mostly benefit from a treatment with dalbavancin and agrees that the design of homogenous and robust studies would allow a broader use of dalbavancin even in other clinical settings.